Ticker

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome announces the publication of positive preclinical results in uveitis, addressing a $3B potential market opportunity.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (NASDAQ: HIND), a clinical-stage biopharmaceutical company focused on developing therapies for serious immuno-inflammatory and rare conditions, today announced that it has filed for Orphan Drug Status for VT-1953, its lead clinical program. Key anticipated benefits of an orphan drug designation include 7 years of U.S. market exclusivity, up to 25% of…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Independent Analyst Values Vyome's VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study.

Medline (NASDAQ: MDLN - Get Free Report) and Vyome (NASDAQ: HIND - Get Free Report) are both manufacturing companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability and risk. Earnings and Valuation This table compares Medline and Vyome"s revenue,